Sanders Morris Harris LLC Buys Shares of 3,150 Alnylam Pharmaceuticals, Inc. $ALNY

Sanders Morris Harris LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 3,150 shares of the biopharmaceutical company’s stock, valued at approximately $1,436,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Aaron Wealth Advisors LLC bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at $506,000. GAMMA Investing LLC lifted its stake in shares of Alnylam Pharmaceuticals by 13.4% in the 3rd quarter. GAMMA Investing LLC now owns 823 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 97 shares during the period. Osaic Holdings Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 132.5% in the 2nd quarter. Osaic Holdings Inc. now owns 3,787 shares of the biopharmaceutical company’s stock valued at $1,202,000 after purchasing an additional 2,158 shares during the period. Orion Porfolio Solutions LLC boosted its position in shares of Alnylam Pharmaceuticals by 11.7% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 4,309 shares of the biopharmaceutical company’s stock valued at $1,405,000 after purchasing an additional 452 shares in the last quarter. Finally, Hudson Bay Capital Management LP boosted its holdings in shares of Alnylam Pharmaceuticals by 138.4% during the 2nd quarter. Hudson Bay Capital Management LP now owns 15,348 shares of the biopharmaceutical company’s stock worth $5,005,000 after buying an additional 55,348 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,129,377.08. The trade was a 13.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,328 shares of company stock valued at $27,288,993 over the last three months. Insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ALNY. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. The Goldman Sachs Group increased their price objective on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright set a $570.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research note on Monday, October 6th. Twenty-three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $477.44.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $391.17 on Wednesday. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The business has a 50-day simple moving average of $449.77 and a two-hundred day simple moving average of $409.43. The company has a market capitalization of $51.68 billion, a P/E ratio of 1,629.88 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.